REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 82.30B
Enterprise value 76.04B
Trailing P/E 20.09
Forward P/E 17.57
PEG ratio (5-yr expected) 1.70
Price/sales (ttm)6.79
Price/book (mrq)3.45
Enterprise value/revenue 6.15
Enterprise value/EBITDA 14.95

Trading information

Stock price history

Beta (5Y monthly) 0.22
52-week change 335.90%
S&P500 52-week change 314.65%
52-week high 3837.55
52-week low 3538.01
50-day moving average 3776.59
200-day moving average 3741.38

Share statistics

Avg vol (3-month) 3567.61k
Avg vol (10-day) 3535.05k
Shares outstanding 5107.89M
Implied shares outstanding 6N/A
Float 8102.52M
% held by insiders 12.54%
% held by institutions 189.64%
Shares short (14 May 2023) 41.21M
Short ratio (14 May 2023) 42.25
Short % of float (14 May 2023) 41.31%
Short % of shares outstanding (14 May 2023) 41.11%
Shares short (prior month 13 Apr 2023) 41.21M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 33.81%
Operating margin (ttm)38.08%

Management effectiveness

Return on assets (ttm)10.44%
Return on equity (ttm)19.27%

Income statement

Revenue (ttm)12.37B
Revenue per share (ttm)115.42
Quarterly revenue growth (yoy)6.60%
Gross profit (ttm)7.02B
Net income avi to common (ttm)4.18B
Diluted EPS (ttm)36.66
Quarterly earnings growth (yoy)-16.00%

Balance sheet

Total cash (mrq)8.96B
Total cash per share (mrq)83.65
Total debt (mrq)2.7B
Total debt/equity (mrq)11.50
Current ratio (mrq)5.45
Book value per share (mrq)219.38

Cash flow statement

Operating cash flow (ttm)4.28B
Levered free cash flow (ttm)1.71B